175 related articles for article (PubMed ID: 37326761)
1. Optimizing reirradiation for relapsed medulloblastoma: identifying the ideal patient and tumor profiles.
Massimino M; Vennarini S; Buttarelli FR; Antonelli M; Colombo F; Minasi S; Pecori E; Ferroli P; Giussani C; Schiariti M; Schiavello E; Biassoni V; Erbetta A; Chiapparini L; Nigro O; Boschetti L; Gianno F; Miele E; Modena P; De Cecco L; Pollo B; Barretta F
J Neurooncol; 2023 Jul; 163(3):577-586. PubMed ID: 37326761
[TBL] [Abstract][Full Text] [Related]
2. Exclusive Hyperfractionated Radiation Therapy and Reduced Boost Volume for Standard-Risk Medulloblastoma: Pooled Analysis of the 2 French Multicentric Studies MSFOP98 and MSFOP 2007 and Correlation With Molecular Subgroups.
Carrie C; Kieffer V; Figarella-Branger D; Masliah-Planchon J; Bolle S; Bernier V; Laprie A; Supiot S; Leseur J; Habrand JL; Alapetite C; Kerr C; Dufour C; Claude L; Chapet S; Huchet A; Bondiau PY; Escande A; Truc G; Nguyen TD; Pasteuris C; Vigneron C; Muracciole X; Bourdeaut F; Appay R; Dubray B; Colin C; Ferlay C; Dussart S; Chabaud S; Padovani L; ;
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1204-1217. PubMed ID: 32768563
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of salvage re-irradiation in recurrent medulloblastoma correlate with age at initial diagnosis, primary risk-stratification, and molecular subgrouping.
Gupta T; Maitre M; Sastri GJ; Krishnatry R; Shirsat N; Epari S; Sahay A; Chinnaswamy G; Patil V; Shetty P; Moiyadi A
J Neurooncol; 2019 Sep; 144(2):283-291. PubMed ID: 31236820
[TBL] [Abstract][Full Text] [Related]
4. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
[TBL] [Abstract][Full Text] [Related]
5. Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.
Zhang ZY; Xu J; Ren Y; Li KK; Ng HK; Mao Y; Zhong P; Yao Y; Zhou LF
PLoS One; 2014; 9(6):e99490. PubMed ID: 24932704
[TBL] [Abstract][Full Text] [Related]
6. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis.
Ramaswamy V; Remke M; Bouffet E; Faria CC; Perreault S; Cho YJ; Shih DJ; Luu B; Dubuc AM; Northcott PA; Schüller U; Gururangan S; McLendon R; Bigner D; Fouladi M; Ligon KL; Pomeroy SL; Dunn S; Triscott J; Jabado N; Fontebasso A; Jones DT; Kool M; Karajannis MA; Gardner SL; Zagzag D; Nunes S; Pimentel J; Mora J; Lipp E; Walter AW; Ryzhova M; Zheludkova O; Kumirova E; Alshami J; Croul SE; Rutka JT; Hawkins C; Tabori U; Codispoti KE; Packer RJ; Pfister SM; Korshunov A; Taylor MD
Lancet Oncol; 2013 Nov; 14(12):1200-7. PubMed ID: 24140199
[TBL] [Abstract][Full Text] [Related]
7. Craniospinal irradiation as part of re-irradiation for children with recurrent medulloblastoma.
Baroni LV; Freytes C; Fernández Ponce N; Oller A; Pinto N; Gonzalez A; Maldonado FR; Sampor C; Rugilo C; Lubieniecki F; Alderete D
J Neurooncol; 2021 Oct; 155(1):53-61. PubMed ID: 34505229
[TBL] [Abstract][Full Text] [Related]
8. Re-irradiation for children with recurrent medulloblastoma in Toronto, Canada: a 20-year experience.
Tsang DS; Sarhan N; Ramaswamy V; Nobre L; Yee R; Taylor MD; Hawkins C; Bartels U; Huang A; Tabori U; Hodgson DC; Bouffet E; Laperriere N
J Neurooncol; 2019 Oct; 145(1):107-114. PubMed ID: 31468270
[TBL] [Abstract][Full Text] [Related]
9. Time, pattern, and outcome of medulloblastoma relapse and their association with tumour biology at diagnosis and therapy: a multicentre cohort study.
Hill RM; Richardson S; Schwalbe EC; Hicks D; Lindsey JC; Crosier S; Rafiee G; Grabovska Y; Wharton SB; Jacques TS; Michalski A; Joshi A; Pizer B; Williamson D; Bailey S; Clifford SC
Lancet Child Adolesc Health; 2020 Dec; 4(12):865-874. PubMed ID: 33222802
[TBL] [Abstract][Full Text] [Related]
10. How ten-years of reirradiation for paediatric high-grade glioma may shed light on first line treatment.
Massimino M; Vennarini S; Barretta F; Colombo F; Antonelli M; Pollo B; Pignoli E; Pecori E; Alessandro O; Schiavello E; Boschetti L; Podda M; Puma N; Gattuso G; Sironi G; Barzanò E; Nigro O; Bergamaschi L; Chiaravalli S; Luksch R; Meazza C; Spreafico F; Terenziani M; Casanova M; Ferrari A; Chisari M; Pellegrini C; Clerici CA; Modena P; Biassoni V
J Neurooncol; 2022 Sep; 159(2):437-445. PubMed ID: 35809148
[TBL] [Abstract][Full Text] [Related]
11. Omission of Upfront Craniospinal Irradiation in Patients with Low-Risk WNT-Pathway Medulloblastoma Is Associated with Unacceptably High Risk of Neuraxial Failure.
Gupta T; Pervez S; Dasgupta A; Chatterjee A; Epari S; Chinnaswamy G; Jalali R
Clin Cancer Res; 2022 Oct; 28(19):4180-4185. PubMed ID: 35653134
[TBL] [Abstract][Full Text] [Related]
12. Treatment results of adults and children with medulloblastoma NCI, Cairo University experience.
Khalil EM
J Egypt Natl Canc Inst; 2008 Jun; 20(2):175-86. PubMed ID: 20029474
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation-Sparing Approaches: An International Cohort Study.
Erker C; Mynarek M; Bailey S; Mazewski CM; Baroni L; Massimino M; Hukin J; Aguilera D; Cappellano AM; Ramaswamy V; Lassaletta A; Perreault S; Kline CN; Rajagopal R; Michaiel G; Zapotocky M; Santa-Maria Lopez V; La Madrid AM; Cacciotti C; Sandler ES; Hoffman LM; Klawinski D; Khan S; Salloum R; Hoppmann AL; Larouche V; Dorris K; Toledano H; Gilheeney SW; Abdelbaki MS; Wilson B; Tsang DS; Knipstein J; Oren MY; Shah S; Murray JC; Ginn KF; Wang ZJ; Fleischhack G; Obrecht D; Tonn S; Harrod VL; Matheson K; Crooks B; Strother DR; Cohen KJ; Hansford JR; Mueller S; Margol A; Gajjar A; Dhall G; Finlay JL; Northcott PA; Rutkowski S; Clifford SC; Robinson G; Bouffet E; Lafay-Cousin L
J Clin Oncol; 2023 Apr; 41(10):1921-1932. PubMed ID: 36548930
[TBL] [Abstract][Full Text] [Related]
14. Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort.
Mynarek M; von Hoff K; Pietsch T; Ottensmeier H; Warmuth-Metz M; Bison B; Pfister S; Korshunov A; Sharma T; Jaeger N; Ryzhova M; Zheludkova O; Golanov A; Rushing EJ; Hasselblatt M; Koch A; Schüller U; von Deimling A; Sahm F; Sill M; Riemenschneider MJ; Dohmen H; Monoranu CM; Sommer C; Staszewski O; Mawrin C; Schittenhelm J; Brück W; Filipski K; Hartmann C; Meinhardt M; Pietschmann K; Haberler C; Slavc I; Gerber NU; Grotzer M; Benesch M; Schlegel PG; Deinlein F; von Bueren AO; Friedrich C; Juhnke BO; Obrecht D; Fleischhack G; Kwiecien R; Faldum A; Kortmann RD; Kool M; Rutkowski S
J Clin Oncol; 2020 Jun; 38(18):2028-2040. PubMed ID: 32330099
[TBL] [Abstract][Full Text] [Related]
15. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.
Schwalbe EC; Lindsey JC; Nakjang S; Crosier S; Smith AJ; Hicks D; Rafiee G; Hill RM; Iliasova A; Stone T; Pizer B; Michalski A; Joshi A; Wharton SB; Jacques TS; Bailey S; Williamson D; Clifford SC
Lancet Oncol; 2017 Jul; 18(7):958-971. PubMed ID: 28545823
[TBL] [Abstract][Full Text] [Related]
16. Postponed is not canceled: role of craniospinal radiation therapy in the management of recurrent infant medulloblastoma--an experience from the HIT-REZ 1997 & 2005 studies.
Müller K; Mynarek M; Zwiener I; Siegler N; Zimmermann M; Christiansen H; Budach W; Henke G; Warmuth-Metz M; Pietsch T; von Hoff K; von Bueren A; Bode U; Rutkowski S; Kortmann RD; Fleischhack G; Tippelt S
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1019-24. PubMed ID: 24661654
[TBL] [Abstract][Full Text] [Related]
17. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.
Zhukova N; Ramaswamy V; Remke M; Pfaff E; Shih DJ; Martin DC; Castelo-Branco P; Baskin B; Ray PN; Bouffet E; von Bueren AO; Jones DT; Northcott PA; Kool M; Sturm D; Pugh TJ; Pomeroy SL; Cho YJ; Pietsch T; Gessi M; Rutkowski S; Bognar L; Klekner A; Cho BK; Kim SK; Wang KC; Eberhart CG; Fevre-Montange M; Fouladi M; French PJ; Kros M; Grajkowska WA; Gupta N; Weiss WA; Hauser P; Jabado N; Jouvet A; Jung S; Kumabe T; Lach B; Leonard JR; Rubin JB; Liau LM; Massimi L; Pollack IF; Shin Ra Y; Van Meir EG; Zitterbart K; Schüller U; Hill RM; Lindsey JC; Schwalbe EC; Bailey S; Ellison DW; Hawkins C; Malkin D; Clifford SC; Korshunov A; Pfister S; Taylor MD; Tabori U
J Clin Oncol; 2013 Aug; 31(23):2927-35. PubMed ID: 23835706
[TBL] [Abstract][Full Text] [Related]
18. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus.
Ramaswamy V; Remke M; Bouffet E; Bailey S; Clifford SC; Doz F; Kool M; Dufour C; Vassal G; Milde T; Witt O; von Hoff K; Pietsch T; Northcott PA; Gajjar A; Robinson GW; Padovani L; André N; Massimino M; Pizer B; Packer R; Rutkowski S; Pfister SM; Taylor MD; Pomeroy SL
Acta Neuropathol; 2016 Jun; 131(6):821-31. PubMed ID: 27040285
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters.
von Bueren AO; Kortmann RD; von Hoff K; Friedrich C; Mynarek M; Müller K; Goschzik T; Zur Mühlen A; Gerber N; Warmuth-Metz M; Soerensen N; Deinlein F; Benesch M; Zwiener I; Kwiecien R; Faldum A; Bode U; Fleischhack G; Hovestadt V; Kool M; Jones D; Northcott P; Kuehl J; Pfister S; Pietsch T; Rutkowski S
J Clin Oncol; 2016 Dec; 34(34):4151-4160. PubMed ID: 27863192
[TBL] [Abstract][Full Text] [Related]
20. Outcome and prognostic factors of desmoplastic medulloblastoma treated within a multidisciplinary treatment concept.
Rieken S; Gaiser T; Mohr A; Welzel T; Witt O; Kulozik AE; Wick W; Debus J; Combs SE
BMC Cancer; 2010 Aug; 10():450. PubMed ID: 20731859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
